You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for New Drug Application (NDA): 018125


✉ Email this page to a colleague

« Back to Dashboard


NDA 018125 describes HALOG, which is a drug marketed by Sun Pharm Inds Inc, Westwood Squibb, and Bristol Myers Squibb, and is included in six NDAs. It is available from two suppliers. Additional details are available on the HALOG profile page.

The generic ingredient in HALOG is halcinonide. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the halcinonide profile page.
Summary for 018125
Tradename:HALOG
Applicant:Bristol Myers Squibb
Ingredient:halcinonide
Patents:0
Medical Subject Heading (MeSH) Categories for 018125

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:OINTMENT;TOPICALStrength0.025%
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.